Equity · Healthcare
AVXL
NASDAQAnavex Life Sciences (AVXL)
The line runs 3.11 USD on 24 August through 0.594 USD on 20 November, on a scale from 0 to 4. Days the market did not trade hold the previous close, flat.
- Market cap
- 55.1M USD
- EPS, diluted, year to Sep 2025
- −0.54 USD
- Avg volume
- 81.5K
as of Nov 20, 2026
Which funds hold Anavex Life Sciences (AVXL)?
7 of the 45 institutional funds we track reported a Anavex Life Sciences position for the quarter ended 30 Sep 2026 — a combined 8.5M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 2,336,420 | 4.7M USD | −23.3% |
| Marshall Wace | Held (±25%) | 758,238 | 1.5M USD | −14.8% |
| Citadel Advisors | Added | 548,819 | 1.1M USD | +66.8% |
| AQR Capital Management | Trimmed | 214,266 | 433K USD | −77.8% |
| D. E. Shaw & Co. | Added | 191,638 | 387K USD | +66.0% |
| Renaissance Technologies | New position | 79,999 | 162K USD | |
| Point72 Asset Management | Trimmed | 77,502 | 157K USD | −50.8% |
| Millennium Management | Exited | |||
| Tudor Investment Corp | Exited |
Have members of Congress traded Anavex Life Sciences (AVXL)?
The most recent congressional trade disclosed in Anavex Life Sciences is a sale by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Sale | 1K USD–15K USD | 39 days |
| 12 Oct 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 35 days |
What has been filed or recorded for Anavex Life Sciences (AVXL)?
The filings we hold for Anavex Life Sciences, newest first: 8 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 5 shares | 7 USD notional · <0.001% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 778 shares | 1K USD notional · 0.001% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 21,210 shares | 28K USD notional · 0.023% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,971 shares | 4K USD notional · 0.003% of shares out |
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 1 USD notional · <0.001% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 20,138 shares | 30K USD notional · 0.022% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 21,139 shares | 33K USD notional · 0.023% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,356 shares | 5K USD notional · 0.004% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.08 USD | |
| 30 Jun 2026 | Financials | Total assets | 120.1M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 112.4M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.06 USD | |
| 31 Dec 2025 | Quarterly earnings | Q1 2026 reported | EPS −0.06 USD | |
| 30 Sep 2025 | Annual report | FY 2025 reported | EPS −0.54 USD | |
| 30 Sep 2025 | Financials | Net income | −46.4M USD | fiscal year |
| 30 Sep 2025 | Financials | Diluted EPS | −0.54 USD | fiscal year |
| 30 Jun 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.16 USD | |
| 31 Mar 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.13 USD | |
| 31 Dec 2024 | Quarterly earnings | Q1 2025 reported | EPS −0.14 USD | |
| 30 Sep 2024 | Annual report | FY 2024 reported | EPS −0.52 USD |
What do people ask about Anavex Life Sciences (AVXL)?
What did Anavex Life Sciences shares close at?0.594
Anavex Life Sciences closed at 0.594 USD on 20 Nov 2026, down 12.95% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Anavex Life Sciences’ market cap?55.1M
Anavex Life Sciences is worth 55.1M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Which funds own Anavex Life Sciences?7 of 45
7 of the 45 funds we track reported a Anavex Life Sciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Marshall Wace and Citadel Advisors. See Funds
Have members of Congress traded Anavex Life Sciences?2 trades
Yes. 2 trades in Anavex Life Sciences appear in the congressional disclosures we hold; the latest is a sale by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Anavex Life Sciences last report earnings?0.08
Anavex Life Sciences last reported earnings on 30 Jun 2026 for Q3 2026, with EPS of 0.08 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words